TCGA-V7-A7HQ-01A-11R-A33J-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.360
- KRAS_SIGNALING_DN+0.320
- MYOGENESIS+0.320
- ESTROGEN_RESPONSE_EARLY+0.310
- OXIDATIVE_PHOSPHORYLATION+0.310
- COAGULATION+0.290
- PANCREAS_BETA_CELLS+0.190
- APICAL_SURFACE+0.180
- XENOBIOTIC_METABOLISM+0.170
- FATTY_ACID_METABOLISM+0.160
Top 10 suppressed
- PROTEIN_SECRETION-0.530
- MITOTIC_SPINDLE-0.520
- G2M_CHECKPOINT-0.510
- E2F_TARGETS-0.450
- TGF_BETA_SIGNALING-0.430
- UV_RESPONSE_DN-0.420
- ANDROGEN_RESPONSE-0.380
- INTERFERON_ALPHA_RESPONSE-0.380
- INTERFERON_GAMMA_RESPONSE-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A3TN-01A-11R-A22K-07 | — | B | 0.934 |
| 2 | TCGA-AC-A3TM-01A-11R-A22K-07 | — | B | 0.898 |
| 3 | TCGA-LL-A50Y-01A-11R-A266-07 | — | B | 0.881 |
| 4 | TCGA-GM-A3XG-01A-31R-A24H-07 | — | A | 0.869 |
| 5 | SRR1410264 | GTEX | — | 0.866 |
| 6 | TCGA-LL-A6FQ-01A-11R-A31O-07 | — | B | 0.858 |
| 7 | SJEPD001534_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.847 |
| 8 | SJEPD001524_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.844 |
| 9 | TCGA-LL-A5YM-01A-11R-A28M-07 | — | B | 0.843 |
| 10 | TCGA-GU-A767-01A-11R-A32O-07 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.020 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.010 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |